Skip to main content
Clinical Trials/NCT01553643
NCT01553643
Unknown
Phase 4

A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis

China Medical University Hospital1 site in 1 country80 target enrollmentJanuary 2010

Overview

Phase
Phase 4
Intervention
Chinese Herb Huang-Chi-Wu-Wu-Tang
Conditions
Intracranial Arterial Stenosis
Sponsor
China Medical University Hospital
Enrollment
80
Locations
1
Primary Endpoint
Primary outcome measure was the improvement hemodynamics at intracranial vessels in the M1 segment of middle cerebral artery (MCA) or basilar artery (BA) shown in transcranial color-coded sonography (TCCS).
Last Updated
14 years ago

Overview

Brief Summary

Intracranial arterial prominent stenosis (IAPS) is one of main cause of stroke especially in Asia. Although antiplatelet aggregative or anticoagulant agent and even surgical operation are used to treat patients with IAPS, the incidence of stroke occurrence still remains high. In addition, symptomatic IAPS most common cause continuous deterioration, thus, increase the incidence of stroke. Therefore, there is a good method to reduce the inceidence of stroke that is to prevent the progressive deterioration of IAPS.

Huang-Chi-Wu-Wu-Tang is made of Astrgalus membranaceus (Fisch.) Gge , Paeonia lactiflora Pall , Cinnamom Twig , Zingiber officinale Rose , Ziziphus jujube Mill , and can treat hemiplegia in the traditional Chinese medicine writings. Astragaloside IV is a component of Astrgalus membranaceus, may reduce th cerebral infarction area in middle cerebral arterial occlusion mice. The investigators previous studies have known that paeoniflorin that a component of Paeonia lactiflora Pall can decrease the cerebral infarction area and neurological deficit in middle cerebral arterial occlusion rats. Therefore, the purpose of the present study was to investigate the effect of Huang-Chi-Wu-Wu-Tang on patients with IAPS.

Registry
clinicaltrials.gov
Start Date
January 2010
End Date
November 2012
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Had received Transcranial Doppolar Sonography.
  • Age \>40 years old.
  • Gender: Male or female.
  • The subject or their legal representative gave written informed consent to participate.
  • Meet with one of the two Transcranial Doppolar Sonography results below:
  • The evaluated standard of MCA M1 stenosis of 50-99% are as follows:
  • PSV \>140 cm/s
  • MFV \>100 cm/s
  • The evaluated standard of BA stenosis of 50-99% are as follows:
  • PSV \>100 cm/s

Exclusion Criteria

  • Refused to sign the Informed Consent Form.
  • Too irritable to accept the evaluation.
  • Age ≦40 years old.
  • Major diseases such as Myocardial Infarction、Heart failure、Chronic pulmonary obstructive disease(COPD)with dyspnea、Liver failure or Renal failure.
  • Pregnancy or breast-feeding.

Arms & Interventions

Chinese Herb Huang-Chi-Wu-Wu-Tang

Intervention: Chinese Herb Huang-Chi-Wu-Wu-Tang

Placebo

Intervention: placebo

Outcomes

Primary Outcomes

Primary outcome measure was the improvement hemodynamics at intracranial vessels in the M1 segment of middle cerebral artery (MCA) or basilar artery (BA) shown in transcranial color-coded sonography (TCCS).

Time Frame: 3 years(all patients)

Study Sites (1)

Loading locations...

Similar Trials